| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013741765 |
| P356 | DOI | 10.1186/AR2045 |
| P932 | PMC publication ID | 1779436 |
| P698 | PubMed publication ID | 16984661 |
| P5875 | ResearchGate publication ID | 6809116 |
| P2093 | author name string | Michael T Nurmohamed | |
| Jos W R Twisk | |||
| Ben A C Dijkmans | |||
| Alexandre E Voskuyl | |||
| Vokko P van Halm | |||
| P2860 | cites work | Atherosclerosis — An Inflammatory Disease | Q26776972 |
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Inflammation in atherosclerosis | Q29547428 | ||
| C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? | Q33678964 | ||
| Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women | Q34067367 | ||
| Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 | ||
| Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity | Q34191742 | ||
| The mortality of rheumatoid arthritis | Q34338843 | ||
| The treatment of unrelated disorders in patients with chronic medical diseases | Q34468642 | ||
| Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis | Q35547305 | ||
| Mortality in rheumatoid arthritis patients with disease onset in the 1980s | Q35548197 | ||
| Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis | Q35548424 | ||
| Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis | Q35553035 | ||
| Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity | Q35799612 | ||
| Is atherosclerosis a complication of long-term corticosteroid treatment? | Q39732969 | ||
| Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 | ||
| Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis | Q44016937 | ||
| Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
| The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. | Q50592760 | ||
| Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. | Q50701881 | ||
| Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. | Q50969877 | ||
| Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines | Q71098333 | ||
| High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors | Q77406810 | ||
| Methotrexate treatment and mortality in rheumatoid arthritis | Q94154076 | ||
| P433 | issue | 5 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | R151 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | |
| P478 | volume | 8 |
| Q36246101 | Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action |
| Q64123686 | An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches |
| Q64882267 | Anti-inflammatory therapy for cardiovascular disease. |
| Q41986719 | Aortic, carotid intima-media thickness and flow- mediated dilation as markers of early atherosclerosis in a cohort of pediatric patients with rheumatic diseases |
| Q36596894 | Atherogenic lipid profiles and its management in patients with rheumatoid arthritis |
| Q37008144 | Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages |
| Q35525108 | Atherosclerosis in systemic lupus erythematosus |
| Q38365624 | Atherosclerotic vascular disease in the autoimmune rheumatologic patient |
| Q38098110 | Biventricular thrombus and associated myocardial infarction in a rheumatoid arthritis patient: a case report and literature review |
| Q90666678 | Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate |
| Q88599465 | Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM) |
| Q63683454 | Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q33943374 | Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment |
| Q35121150 | Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions |
| Q36757060 | Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study |
| Q47940789 | Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China |
| Q37688153 | Cardiovascular disease is preventable among women |
| Q37859676 | Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity |
| Q35617716 | Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q33806651 | Cardiovascular morbidity and mortality in rheumatoid arthritis |
| Q99240510 | Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout |
| Q38090373 | Cardiovascular risk in juvenile idiopathic arthritis |
| Q34563216 | Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment |
| Q38124279 | Cardiovascular risk in the rheumatic disease patient undergoing orthopedic surgery |
| Q37956137 | Cardiovascular safety of biologic therapies for the treatment of RA. |
| Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
| Q37424983 | Chloroquine in glioblastoma--new horizons for an old drug |
| Q37026106 | Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? |
| Q84311215 | Decreased heart rate variability in patients with psoriatic arthritis |
| Q45973867 | Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients? |
| Q37267458 | Effects of Methotrexate in a Rabbit Model of In-Stent Neoatherosclerosis: An Optical Coherence Tomography Study. |
| Q34238357 | Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity |
| Q36877859 | Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients |
| Q37158219 | Hypertension in rheumatoid arthritis. |
| Q51781155 | Increased occurrence of cardiovascular events and comorbidities in a general rheumatology cohort. |
| Q37281848 | Inflammation and hypertension in rheumatoid arthritis |
| Q92256742 | Inflammation as a Therapeutic Target in Atherosclerosis |
| Q37330955 | Inflammatory cell infiltrates in the heart of patients with coronary artery disease with and without inflammatory rheumatic disease: a biopsy study |
| Q38722298 | Inflammatory cytokines in atherosclerosis: current therapeutic approaches. |
| Q52982204 | Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis. |
| Q45265863 | Left ventricular morphology and function in patients with rheumatoid arthritis |
| Q33482833 | Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis |
| Q38554197 | Lipid and Metabolic Changes in Rheumatoid Arthritis. |
| Q46195508 | Lipid profile and anti-TNF-α use. |
| Q47959078 | Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis. |
| Q36182351 | Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis |
| Q37428743 | Management of cardiovascular disease risk in chronic inflammatory disorders |
| Q37058791 | Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion |
| Q35471696 | Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells |
| Q41718646 | Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. |
| Q48254045 | Might psoriasis be a risk factor for obstructive sleep apnea syndrome? |
| Q56966479 | Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in t |
| Q38893238 | Neutropenia in the Elderly: A Rheumatology Perspective |
| Q37079259 | Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. |
| Q81786177 | Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis |
| Q34559803 | Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? |
| Q92771536 | Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis |
| Q37730557 | Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. |
| Q38122932 | Potential benefits of green tea polyphenol EGCG in the prevention and treatment of vascular inflammation in rheumatoid arthritis |
| Q46089585 | Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis |
| Q36951050 | Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors |
| Q64239598 | Prescribing Trend of Antirheumatic Drugs in Taiwan and Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study |
| Q41466368 | Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment |
| Q53502883 | Prevention of stroke in rheumatoid arthritis. |
| Q40459284 | Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. |
| Q28709376 | Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis |
| Q24630655 | Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity |
| Q31005025 | Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data |
| Q59135667 | Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate |
| Q82076745 | Rheumatoid arthritis and cardiovascular disease |
| Q36812587 | Rheumatoid arthritis and cardiovascular disease: an update on treatment issues |
| Q35124825 | Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. |
| Q59352564 | Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314 |
| Q36709328 | Semiquantified noncalcified coronary plaque in systemic lupus erythematosus |
| Q37245188 | Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis |
| Q35377706 | Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease |
| Q92885360 | Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection |
| Q49787347 | The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients |
| Q33848290 | The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study. |
| Q37427394 | The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis |
| Q37640953 | The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review |
| Q35135831 | The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. |
| Q34519563 | The homocysteine controversy |
| Q50233845 | Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk |
| Q85069909 | Therapy of dyslipidemia in rheumatic diseases |
| Q38267703 | Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? |
| Q88979499 | Treat-to-target therapy does not prevent excessive progression of carotid intima media thickness during the first year of therapy in early rheumatoid arthritis |
| Q44293608 | Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis |
| Q28074148 | What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? |
| Q85589116 | [Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis] |
Search more.